Patient characteristics
| Pretransplant demographics . | |||
|---|---|---|---|
| . | mGFR <65 mL/min/1.73 m2 . | mGFR ≥65 mL/min/1.73 m2 . | Total . |
| (n = 22) . | (n = 87) . | (N = 109) . | |
| Age, median (range), y | 66.1 (48.8-75.1) | 63.8 (33.8-75.0) | 64.6 (33.8-75.1) |
| Recipient-donor sex | |||
| F-F | 5 (22.7%) | 14 (16.1%) | 19 (17.4%) |
| F-M | 6 (27.3%) | 26 (29.9%) | 32 (29.4%) |
| M-F | 4 (18.2%) | 15 (17.2%) | 19 (17.4%) |
| M-M | 7 (31.8%) | 32 (36.8%) | 39 (35.8%) |
| Comorbidity Index, median (range) | 5.0 (2.0-10.0) | 5.0 (2.0-12.0) | 5.0 (2.0-12.0) |
| Disease | |||
| AML | 18 (81.8%) | 54 (62.1%) | 72 (66.1%) |
| MDS | 4 (18.2%) | 33 (37.9%) | 37 (33.9%) |
| Disease status at transplant | |||
| CR1 | 17 (77.3%0 | 56 (64.4%) | 73 (67.0%) |
| CR2 | 2 (9.1%) | 17 (19.5%) | 19 (17.4%) |
| Progressed/active | 3 (13.6%) | 14 (16.1%) | 17 (15.6%) |
| Donor type | |||
| Related | 12 (54.4%) | 49 (56.3%) | 61 (56.0%) |
| Unrelated | 10 (45.5%) | 38 (43.7%) | 48 (44.0%) |
| HLA match | |||
| Matched | 22 (100.0%) | 86 (98.9%) | 108 (99.1%) |
| Mismatched | 0 (0.0%) | 1 (1.1%) | 1 (0.9%) |
| Graft type | |||
| Peripheral blood | 22 (100%) | 84 (96.6%) | 106 (97.2%) |
| Bone marrow | 0 (0.0%) | 3 (3.4%) | 3 (2.8%) |
| Pretransplant kidney function | |||
| Creatinine, median (range), mg/dL | 1.1 (0.5-1.6) | 0.8 (0.4-1.3) | 0.9 (0.4-1.6) |
| Corrected iothalamate, median (range), mL/min/1.73 m2 | 50 (34-64) | 85 (65.0-146) | 81 (34.0-146) |
| eCrCl, median (range), mL/min | 74.6 (46.9-130.4) | 89.8 (53.8-203.9) | 87.1 (46.9-203.9) |
| eGFR, median (range), mL/min/1.73 m2 | 65.4 (32.1-133) | 81.1 (46.5-154.9) | 79.2 (32.1-154.9) |
| Posttransplant characteristics | |||
| Time to engraftment, median (range), d | 16 (11-36) | 15 (6-191) | 16 (6-191) |
| GVHD* | |||
| Acute GVHD | 13 (64.6%) | 47 (56.7%) | 60 (58.1%) |
| Chronic GVHD | 12 (54.8%) | 58 (56.2%) | 70 (55.8%) |
| Pretransplant demographics . | |||
|---|---|---|---|
| . | mGFR <65 mL/min/1.73 m2 . | mGFR ≥65 mL/min/1.73 m2 . | Total . |
| (n = 22) . | (n = 87) . | (N = 109) . | |
| Age, median (range), y | 66.1 (48.8-75.1) | 63.8 (33.8-75.0) | 64.6 (33.8-75.1) |
| Recipient-donor sex | |||
| F-F | 5 (22.7%) | 14 (16.1%) | 19 (17.4%) |
| F-M | 6 (27.3%) | 26 (29.9%) | 32 (29.4%) |
| M-F | 4 (18.2%) | 15 (17.2%) | 19 (17.4%) |
| M-M | 7 (31.8%) | 32 (36.8%) | 39 (35.8%) |
| Comorbidity Index, median (range) | 5.0 (2.0-10.0) | 5.0 (2.0-12.0) | 5.0 (2.0-12.0) |
| Disease | |||
| AML | 18 (81.8%) | 54 (62.1%) | 72 (66.1%) |
| MDS | 4 (18.2%) | 33 (37.9%) | 37 (33.9%) |
| Disease status at transplant | |||
| CR1 | 17 (77.3%0 | 56 (64.4%) | 73 (67.0%) |
| CR2 | 2 (9.1%) | 17 (19.5%) | 19 (17.4%) |
| Progressed/active | 3 (13.6%) | 14 (16.1%) | 17 (15.6%) |
| Donor type | |||
| Related | 12 (54.4%) | 49 (56.3%) | 61 (56.0%) |
| Unrelated | 10 (45.5%) | 38 (43.7%) | 48 (44.0%) |
| HLA match | |||
| Matched | 22 (100.0%) | 86 (98.9%) | 108 (99.1%) |
| Mismatched | 0 (0.0%) | 1 (1.1%) | 1 (0.9%) |
| Graft type | |||
| Peripheral blood | 22 (100%) | 84 (96.6%) | 106 (97.2%) |
| Bone marrow | 0 (0.0%) | 3 (3.4%) | 3 (2.8%) |
| Pretransplant kidney function | |||
| Creatinine, median (range), mg/dL | 1.1 (0.5-1.6) | 0.8 (0.4-1.3) | 0.9 (0.4-1.6) |
| Corrected iothalamate, median (range), mL/min/1.73 m2 | 50 (34-64) | 85 (65.0-146) | 81 (34.0-146) |
| eCrCl, median (range), mL/min | 74.6 (46.9-130.4) | 89.8 (53.8-203.9) | 87.1 (46.9-203.9) |
| eGFR, median (range), mL/min/1.73 m2 | 65.4 (32.1-133) | 81.1 (46.5-154.9) | 79.2 (32.1-154.9) |
| Posttransplant characteristics | |||
| Time to engraftment, median (range), d | 16 (11-36) | 15 (6-191) | 16 (6-191) |
| GVHD* | |||
| Acute GVHD | 13 (64.6%) | 47 (56.7%) | 60 (58.1%) |
| Chronic GVHD | 12 (54.8%) | 58 (56.2%) | 70 (55.8%) |
CR1, first complete remission; CR2, second complete remission; F, female; M, male.
Rates presented are cumulative incidence rates at 1 year, and P values are from Cox proportional hazards regression.